Event-Free and Overall Survival With Dapagliflozin in Heart Failure and Reduced Ejection Fraction Original Investigation Research Group Information: The DAPA-HF Investigators 9. Vaduganathan M, Claggett BL, Juraschek SP, 16. Butt JH, Docherty KF, Petrie MC, et al. Efficacy and Committees are listed Supplement 3. Solomon SD. Assessment of long-term benefit of and safety of dapagliflozin in men and women with intensive blood pressure control on residual life heart failure with reduced ejection fraction: Data Sharing Statement: See Supplement 4. span: secondary analysis of the Systolic Blood a prespecified analysis of the dapagliflozin and Pressure Intervention Trial (SPRINT). JAMA Cardiol. prevention of adverse outcomes in heart failure REFERENCES 2020;5(5):576-581. doi:10.1001/jamacardio.2019. trial. JAMA Cardiol. 2021;6(6):678-689. doi:10. 1. McMurray JJV, Solomon SD, Inzucchi SE, et al; 6192 1001/jamacardio.2021.0379 DAPA-HF Trial Committees and Investigators. 10. Vaduganathan M, Claggett BL, Jhund PS, et al. 17. Martinez FA, Serenelli M, Nicolau JC, et al. Dapagliflozin in patients with heart failure and Estimating lifetime benefits of comprehensive Efficacy and safety of dapagliflozin in heart failure reduced ejection fraction. N Engl J Med. 2019;381 disease-modifying pharmacological therapies in with reduced ejection fraction according to age: (21):1995-2008. doi:10.1056/NEJMoa1911303 patients with heart failure with reduced ejection insights from DAPA-HF.
JAMA Cardiology – American Medical Association
Published: Nov 28, 2021